Sector News

Relay adds execs as it transitions to the development stage

December 5, 2018
Life sciences

Former Fierce 15 winner Relay Therapeutics has brought on Verastem’s Mahesh Padval, Ph.D., and Eli Lilly’s Mary Mader, Ph.D., to boost its drug discovery and development operations in oncology as it begins to transition to an R&D-stage biotech.

Padval was appointed as Relay’s senior VP of pharmaceutical drug development, while Mader was named VP of chemistry.

At Verastem, Padval served as VP of pharmaceutical sciences and product development, helping to oversee preclinical development, CMC and clinical pharmacology activities—including for the September approval and launch of Copiktra in third-line chronic lymphocytic leukemia, small lymphocytic leukemia and follicular lymphoma, which is expected to reach between $500 million and $850 million in peak sales.

Prior to Verastem, Padval was VP of preclinical development and formulations at Zalicus, and he also held roles at Charles River Discovery and Development Services and Genzyme Transgenics.

Mader previously served as a senior research advisory and a research fellow at Eli Lilly, where she worked on the discovery and development of multiple clinical candidates. Before that, she was a visiting research scientist at the Bayer Research Center and an associate professor at Grinnell College in Iowa.

Relay’s pipeline focuses on studying the movement of proteins within cells in real-time. Its discovery engine examines the full mobility of a protein and the ways that motion can regulate function.

The company’s head of R&D, Don Bergstrom, M.D., Ph.D., said the company plans to expand its protein motion platform to an “expanding array of therapeutic targets” as it transitions to the development stage.

By Conor Hale

Source: Fierce Biotech

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend